XML 72 R49.htm IDEA: XBRL DOCUMENT
v3.19.3.a.u2

Earnings (Loss) per Share (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2019
Schedule of Earnings per Share | The net income attributable to Teva and the weighted average number of ordinary shares used in the computation of basic and diluted loss per share for the years ended December 31, 2019, 2018 and 2017 are as follows:
|  | 2019 |  |  | 2018 |  |  | 2017 |
|  | (U.S. $ in millions, except share data) |
Net income (loss) used for the computation of diluted loss per share |  | $ | (999 | ) |  | $ | (2,399 | ) |  | $ | (16,525 | )
Weighted average number of shares used in the computation of basic loss per share |  |  | 1,091 |  |  |  | 1,021 |  |  |  | 1,016 |
Add: |  |  |  |  |  |  |  |  |  |  |  |
Weighted average number of shares used in the computation of diluted loss per share |  |  | 1,091 |  |  |  | 1,021 |  |  |  | 1,016 |

X
- Definition Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257 + Details
Name: | us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration